Literature DB >> 33284579

Contribution of the P2X4 Receptor in Rat Hippocampus to the Comorbidity of Chronic Pain and Depression.

Lin Li1,2, Yuting Zou3, Baoe Liu3, Runan Yang1,2, Jingjian Yang4, Minghao Sun3, Zijing Li3, Xiumei Xu1,2, Guilin Li1,2, Shuangmei Liu1,2, Wolfgang Greffrath5, Rolf-Detlef Treede5, Guodong Li1,2, Shangdong Liang1,2.   

Abstract

The hippocampus is an important region for the interaction between depression and pain. Studies show that the P2X4 receptor plays key role in neuropathic pain. This work investigated the potential implication of the P2X4 receptor in the hippocampus in comorbidity of chronic pain and depression. The rat model induced by chronic constriction injury (CCI) plus unpredictable chronic mild stress (UCMS) was used in this study. Our data showed that CCI plus UCMS treatment resulted in abnormal changes in pain and depressive-like behaviors in the rat, accompanied by the upregulated expression of P2X4, NLRP3 (NOD-like receptor protein 3) inflammasome, and interleukin-1β and the activation of p38 MAPK in the hippocampus. The P2X4 antagonist 5-BDBD reversed these abnormal changes in the hippocampus, relieved hippocampal neuronal damage, and alleviated the abnormal pain and depressive-like behaviors in the CCI plus UCMS treated rats. These findings suggest that the P2X4 receptor in the hippocampus may mediate and significantly contribute to the pathological processes of comorbid pain and depression.

Entities:  

Keywords:  P2X4 receptor; comorbidity of pain and depression; hippocampus; neuropathic pain; unpredictable chronic mild stress

Mesh:

Substances:

Year:  2020        PMID: 33284579     DOI: 10.1021/acschemneuro.0c00623

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   5.780


  7 in total

Review 1.  Targeting purinergic receptors to attenuate inflammation of dry eye.

Authors:  Jia-Ning Wang; Hua Fan; Jian-Tao Song
Journal:  Purinergic Signal       Date:  2022-02-26       Impact factor: 3.765

2.  Pinocembrin Inhibits P2X4 Receptor-Mediated Pyroptosis in Hippocampus to Alleviate the Behaviours of Chronic Pain and Depression Comorbidity in Rats.

Authors:  Runan Yang; Jingjian Yang; Zijing Li; Ruichen Su; Lifang Zou; Lin Li; Xiumei Xu; Guilin Li; Shuangmei Liu; Shangdong Liang; Changshui Xu
Journal:  Mol Neurobiol       Date:  2022-09-10       Impact factor: 5.682

3.  Alterations of monoamine neurotransmitters, HPA-axis hormones, and inflammation cytokines in reserpine-induced hyperalgesia and depression comorbidity rat model.

Authors:  Jingjie Zhao; Wei Shi; Yujia Lu; Xuesong Gao; Anna Wang; Shan Zhang; Yi Du; Yongzhi Wang; Li Li
Journal:  BMC Psychiatry       Date:  2022-06-22       Impact factor: 4.144

4.  Gray matter volume reduction with different disease duration in trigeminal neuralgia.

Authors:  Shanshan Shen; Huifeng Zheng; Jianwei Wang; Wenchang Guo; Xiaowan Guo; Hong Ji; Shuqian Zhang; Yingmin Chen; Gaofeng Shi
Journal:  Neuroradiology       Date:  2021-08-28       Impact factor: 2.804

Review 5.  Purinergic signaling: a potential therapeutic target for depression and chronic pain.

Authors:  Yuting Zou; Runan Yang; Lin Li; Xiumei Xu; Shangdong Liang
Journal:  Purinergic Signal       Date:  2021-08-02       Impact factor: 3.765

6.  Role of P2X4/NLRP3 Pathway-Mediated Neuroinflammation in Perioperative Neurocognitive Disorders.

Authors:  Hui Yuan; Bo Lu; Yiqin Ji; Bo Meng; Ruichun Wang; Daofan Sun; Rongjun Liu; Xiaojie Zhai; Xiaoyu Li; Jinling Qin; Junping Chen
Journal:  Mediators Inflamm       Date:  2022-02-01       Impact factor: 4.711

7.  Activation of the dorsal, but not the ventral, hippocampus relieves neuropathic pain in rodents.

Authors:  Xuhong Wei; Maria Virginia Centeno; Wenjie Ren; Anna Maria Borruto; Daniele Procissi; Ting Xu; Rami Jabakhanji; Zuchao Mao; Haram Kim; Yajing Li; Yiyuan Yang; Philipp Gutruf; John A Rogers; D James Surmeier; Jelena Radulovic; Xianguo Liu; Marco Martina; Apkar Vania Apkarian
Journal:  Pain       Date:  2021-12-01       Impact factor: 6.961

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.